Proteomic Assessment of the Risk of Secondary Cardiovascular Events among Individuals with CKD.

IF 9.4 1区 医学 Q1 UROLOGY & NEPHROLOGY Journal of The American Society of Nephrology Pub Date : 2024-09-26 DOI:10.1681/asn.0000000502
Rajat Deo,Ruth F Dubin,Yue Ren,Jianqiao Wang,Harold Feldman,Haochang Shou,Josef Coresh,Morgan E Grams,Aditya L Surapaneni,Jordana B Cohen,Mayank Kansal,Mahboob Rahman,Mirela Dobre,Jiang He,Tanika Kelly,Alan S Go,Paul L Kimmel,Ramachandran S Vasan,Mark R Segal,Hongzhe Li,Peter Ganz
{"title":"Proteomic Assessment of the Risk of Secondary Cardiovascular Events among Individuals with CKD.","authors":"Rajat Deo,Ruth F Dubin,Yue Ren,Jianqiao Wang,Harold Feldman,Haochang Shou,Josef Coresh,Morgan E Grams,Aditya L Surapaneni,Jordana B Cohen,Mayank Kansal,Mahboob Rahman,Mirela Dobre,Jiang He,Tanika Kelly,Alan S Go,Paul L Kimmel,Ramachandran S Vasan,Mark R Segal,Hongzhe Li,Peter Ganz","doi":"10.1681/asn.0000000502","DOIUrl":null,"url":null,"abstract":"BACKGROUND\r\nCardiovascular risk models have been developed primarily for incident events. Well-performing models are lacking to predict secondary cardiovascular events among people with a history of coronary heart disease, stroke, or heart failure who also have chronic kidney disease (CKD). We sought to develop a proteomics-based risk score for cardiovascular events in individuals with CKD and a history of cardiovascular disease.\r\n\r\nMETHODS\r\nWe measured 4638 plasma proteins among 1067 participants from the Chronic Renal Insufficiency Cohort (CRIC) and 536 individuals from the Atherosclerosis Risk in Communities Cohort (ARIC). All had non-dialysis-dependent CKD and coronary heart disease, heart failure, or stroke at study baseline. A proteomic risk model for secondary cardiovascular events was derived by elastic net regression in CRIC, validated in ARIC, and compared to clinical models. Biologic mechanisms of secondary events were characterized through proteomic pathway analysis.\r\n\r\nRESULTS\r\nA 16-protein risk model was superior to the Framingham risk score for secondary events, including a modified score that included estimated glomerular filtration rate (eGFR). In CRIC, the annualized area under the receiver operating characteristic (AUC) within 1 to 5 years ranged between 0.77 and 0.80 for the protein model and 0.57 and 0.72 for the clinical models. These findings were replicated in the ARIC validation cohort. Biologic pathway analysis identified pathways and proteins for cardiac remodeling and fibrosis, vascular disease, and thrombosis.\r\n\r\nCONCLUSIONS\r\nThe proteomic risk model for secondary cardiovascular events outperformed clinical models based on traditional risk factors and eGFR.","PeriodicalId":17217,"journal":{"name":"Journal of The American Society of Nephrology","volume":"76 1","pages":""},"PeriodicalIF":9.4000,"publicationDate":"2024-09-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of The American Society of Nephrology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1681/asn.0000000502","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"UROLOGY & NEPHROLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

BACKGROUND Cardiovascular risk models have been developed primarily for incident events. Well-performing models are lacking to predict secondary cardiovascular events among people with a history of coronary heart disease, stroke, or heart failure who also have chronic kidney disease (CKD). We sought to develop a proteomics-based risk score for cardiovascular events in individuals with CKD and a history of cardiovascular disease. METHODS We measured 4638 plasma proteins among 1067 participants from the Chronic Renal Insufficiency Cohort (CRIC) and 536 individuals from the Atherosclerosis Risk in Communities Cohort (ARIC). All had non-dialysis-dependent CKD and coronary heart disease, heart failure, or stroke at study baseline. A proteomic risk model for secondary cardiovascular events was derived by elastic net regression in CRIC, validated in ARIC, and compared to clinical models. Biologic mechanisms of secondary events were characterized through proteomic pathway analysis. RESULTS A 16-protein risk model was superior to the Framingham risk score for secondary events, including a modified score that included estimated glomerular filtration rate (eGFR). In CRIC, the annualized area under the receiver operating characteristic (AUC) within 1 to 5 years ranged between 0.77 and 0.80 for the protein model and 0.57 and 0.72 for the clinical models. These findings were replicated in the ARIC validation cohort. Biologic pathway analysis identified pathways and proteins for cardiac remodeling and fibrosis, vascular disease, and thrombosis. CONCLUSIONS The proteomic risk model for secondary cardiovascular events outperformed clinical models based on traditional risk factors and eGFR.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
对慢性肾脏病患者继发性心血管事件风险的蛋白质组学评估
背景心血管风险模型主要是针对突发事件而开发的。对于有冠心病、中风或心力衰竭病史且同时患有慢性肾脏病(CKD)的人,目前还缺乏性能良好的模型来预测继发性心血管事件。我们对慢性肾功能不全队列(CRIC)的 1067 名参与者和社区动脉粥样硬化风险队列(ARIC)的 536 名参与者的 4638 种血浆蛋白质进行了测量。这些人在研究基线时均患有非透析依赖型慢性肾脏病和冠心病、心力衰竭或中风。在 CRIC 中通过弹性净回归得出了继发性心血管事件的蛋白质组风险模型,在 ARIC 中进行了验证,并与临床模型进行了比较。结果在继发性心血管事件方面,16 种蛋白风险模型优于弗明翰风险评分,包括包括估计肾小球滤过率 (eGFR) 的修改评分。在 CRIC 中,蛋白质模型在 1 至 5 年内的年化接收器操作特征下面积(AUC)介于 0.77 和 0.80 之间,临床模型介于 0.57 和 0.72 之间。这些结果在ARIC验证队列中得到了重复。结论:继发性心血管事件的蛋白质组风险模型优于基于传统风险因素和 eGFR 的临床模型。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Journal of The American Society of Nephrology
Journal of The American Society of Nephrology 医学-泌尿学与肾脏学
CiteScore
22.40
自引率
2.90%
发文量
492
审稿时长
3-8 weeks
期刊介绍: The Journal of the American Society of Nephrology (JASN) stands as the preeminent kidney journal globally, offering an exceptional synthesis of cutting-edge basic research, clinical epidemiology, meta-analysis, and relevant editorial content. Representing a comprehensive resource, JASN encompasses clinical research, editorials distilling key findings, perspectives, and timely reviews. Editorials are skillfully crafted to elucidate the essential insights of the parent article, while JASN actively encourages the submission of Letters to the Editor discussing recently published articles. The reviews featured in JASN are consistently erudite and comprehensive, providing thorough coverage of respective fields. Since its inception in July 1990, JASN has been a monthly publication. JASN publishes original research reports and editorial content across a spectrum of basic and clinical science relevant to the broad discipline of nephrology. Topics covered include renal cell biology, developmental biology of the kidney, genetics of kidney disease, cell and transport physiology, hemodynamics and vascular regulation, mechanisms of blood pressure regulation, renal immunology, kidney pathology, pathophysiology of kidney diseases, nephrolithiasis, clinical nephrology (including dialysis and transplantation), and hypertension. Furthermore, articles addressing healthcare policy and care delivery issues relevant to nephrology are warmly welcomed.
期刊最新文献
Streamlining the Histopathological Workflow in Diabetic Kidney Disease with Artificial Intelligence. The Story of Aldosterone Escape. SGLT2 Inhibitors in ADPKD: Mechanistic Insights and Therapeutic Promise. Dissecting Normal and Abnormal Human Kidney Development Using Multi-omics. Redefining Immunosuppression in Older Kidney Transplant Recipients: Reflections on the OPTIMIZE Study.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1